Biotinylated Canine CD20/MS4A1 Nanodisc
Catalog No: CD20-DB001
- Species
- Canine
- Expression System
- HEK293
- Tag
- His
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Canine CD20/MS4A1 Nanodisc is expressed in HEK293 cells with a His tag at the C-terminus. It contains amino acid residues Met1-Pro297 (UniProt accession: Q3C2E2).
Product Details
- Molecular Aliases
- MS4A1; CD20; MS4A-1; B1; Bp35; CD20 receptor; CD20S7; CVID5; LEU-16; Ly-44; MS4A2; S7; LEU16; Ly44
- Protein Length
- Met1-Pro297
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 46.01 kDa.
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Supplied as 0.22 μm filtered solution in PBS, 200mM L-arginine (pH 7.4). Notice: Not recommended for flow cytometry in mammalian cells.
- State
- Liquid
- Storage Conditions
- Valid for 6 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Data Display
Immobilized Biotinylated Canine CD20 Nanodisc, His Tag at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-CD20 Antibody, hFc Tag with the EC50 of 3.7ng/ml determined by ELISA. (QC Test)
Biotinylated Canine CD20 Nanodisc, His Tag captured on CM5 Chip via Streptavidin can bind Anti-CD20 Antibody, hFc Tag with an affinity constant of 1.01 nM as determined in SPR assay (Biacore S200).
Background
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R, CD117) and progressively increasing in concentration until maturity. CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
References
- Ma D, Mcdevitt M R, Barendswaard E, et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies[J]. Leukemia, 2002, 16(1):60-66.
- Jager U, Fridrik M, Zeitlinger M, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response[J]. Haematologica, 2012, 97(9):1431-1438.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.